Embolization Versus Embolization Plus Systemic Therapy in HCC
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective analysis that evaluated embolization versus embolization plus systemic therapy in patients with hepatocellular carcinoma and metastatic disease.
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective analysis that evaluated embolization versus embolization plus systemic therapy in patients with hepatocellular carcinoma and metastatic disease.
Clinical Pearls:
- Patients with HCC that were given only embolization fared worse than patients in the control arm, who received sorafenib alone
- The median survival in the embolization-only arm was 6-7 months while median survival in the control arm was 10.7 months
- When patients received embolization plus systemic therapy, the median survival was greater than 1 year
- The idea of combining embolization and systemic therapy needs to be studied further
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
